Search Results - "Nastoupil, LJ"

REAL-WORLD SEQUENTIAL USE OF CD19-DIRECTED THERAPIES FOR RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: TAFASITAMAB PRECEDING CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY by N Epperla, LJ Nastoupil, B Feinberg, J Galvin, P Pathak, T Amoloja, D Gentile, K Saverno

“…Objectives: Potential CD19 antigen loss following CD19-directed therapy has raised concerns over sequential use of these therapies, and real-world data are…”
Get full text

REAL-WORLD USE OF TAFASITAMAB FOR RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN THE UNITED STATES BY PRIMARY REFRACTORY STATUS by K Saverno, KMZ Savill, B Feinberg, J Galvin, P Pathak, T Amoloja, N Epperla, LJ Nastoupil

“…Objectives: Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma with variable prognoses. Patients with primary refractory DLBCL tend to have poor…”
Get full text

REAL-WORLD USE OF TAFASITAMAB FOR RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN THE UNITED STATES BY AGE GROUP (> 70 YEARS AND 70 YEARS) by N Epperla, LJ Nastoupil, KMZ Savill, B Feinberg, J Galvin, P Pathak, T Amoloja, M Vukcevic, K Saverno

“…Objectives: Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of lymphoma that occurs more frequently in older adults. Tafasitamab, a CD19-targeting…”
Get full text

Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study by Morschhauser, Franck, Dahiya, Saurabh, Palomba, M. Lia, Martin Garcia-Sancho, Alejandro, Reguera Ortega, Juan Luis, Kuruvilla, John, Jäger, Ulrich, Cartron, Guillaume, Izutsu, Koji, Dreyling, Martin, Kahl, Brad, Ghesquieres, Hervé, Ardeshna, Kirit, Goto, Hideki, Barbui, Anna Maria, Abramson, Jeremy S., Borchmann, Peter, Fleury, Isabelle, Mielke, Stephan, Skarbnik, Alan, de Vos, Sven, Kamdar, Manali, Karmali, Reem, Viardot, Andreas, Farazi, Thalia, Fasan, Omotayo, Lymp, James, Vedal, Min, Nishii, Rina, Avilion, Ariel, Papuga, Jessica, Kumar, Jinender, Nastoupil, Loretta J.

“…An unmet need exists for patients with relapsed/refractory (R/R) follicular lymphoma (FL) and high-risk disease features, such as progression of disease within…”
Get full text

Author Correction: Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study by Morschhauser, Franck, Dahiya, Saurabh, Palomba, M. Lia, Martin Garcia-Sancho, Alejandro, Reguera Ortega, Juan Luis, Kuruvilla, John, Jäger, Ulrich, Cartron, Guillaume, Izutsu, Koji, Dreyling, Martin, Kahl, Brad, Ghesquieres, Hervé, Ardeshna, Kirit, Goto, Hideki, Barbui, Anna Maria, Abramson, Jeremy S., Borchmann, Peter, Fleury, Isabelle, Mielke, Stephan, Skarbnik, Alan, de Vos, Sven, Kamdar, Manali, Karmali, Reem, Viardot, Andreas, Farazi, Thalia, Fasan, Omotayo, Lymp, James, Vedal, Min, Nishii, Rina, Avilion, Ariel, Papuga, Jessica, Kumar, Jinender, Nastoupil, Loretta J.

Get full text

Personalised therapy in follicular lymphoma - is the dial turning? by Linton, Kim M, Specht, Lena, Pavlovsky, Astrid, Thompson, Carrie A, Kimby, Eva, de Jong, Daphne, Nastoupil, Loretta J, Cottereau, Anne-Ségolène, Casulo, Carla, Sarkozy, Clémentine, Okosun, Jessica

“…Follicular lymphoma is the most common indolent lymphoma accounting for approximately 20%-25% of all new non-Hodgkin lymphoma diagnoses in western countries…”
Get full text

FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma by Maurer, Matthew J., Prochazka, Vit K, Flowers, Christopher R., Jakobsen, Lasse Hjort, Villa, Diego, Weibull, Caroline E., Cahn, Elliot J., Smith, Alexandra, Ghesquieres, Herve, Kridel, Robert, Gandhi, Maher, Cheah, Chan Y., Hawkes, Eliza, Seymour, John F., Freeman, Ciara L., Clausen, Michael Roost, Wahlin, Björn E, Friedberg, Jonathan W., Casulo, Carla, Habermann, Thomas M., Wang, Yucai, Nastoupil, Loretta J., Brown, Peter De Nully, Belada, David, Janíková, Andrea, Mocikova, Heidi, Fürst, Tomáš, Burack, Richard, Martin, Peter, Cohen, Jonathon B., Lossos, Izidore S., Kahl, Brad S., Link, Brian K., Smedby, Karin E., Sehn, Laurie H., Trneny, Marek, El-Galaly, Tarec Christoffer Christoffer, Cerhan, James R.

Get full text

TRANSCEND FL: Phase II Study Results of Lisocabtagene Maraleucel (Liso-Cel) in Patients With R/R Follicular Lymphoma (FL) by Nastoupil, LJ, Dahiya, S, Palomba, ML, Garcia-Sancho, AM, Ortega, JLR, Kuruvilla, J, Jager, U, Cartron, G, Izutsu, KI, Dreyling, M, Kahl, B, Ghesquieres, H, Ardeshna, K, Goto, H, Barbui, AM, Abramson, JS, Borchmann, P, Fleury, I, Mielke, S, Farazi, T, Fasan, O, Lymp, J, Vedal, M, Nishii, R, Avilion, A, Papuga, J, Morschhauser, F

Get full text

TRANSCEND FL: Phase 2 Study Primary Analysis of Lisocabtagene Maraleucel as SecondLine Therapy in Patients with High-Risk Relapsed or Refractory Follicular Lymphoma by Morschhauser, F, Dahiya, S, Palomba, ML, Garcia-Sancho, AM, Reguera, JL, Kuruvilla, J, Jaeger, U, Cartron, G, Izutsu, K, Dreyling, M, Kahl, BS, Ghesquieres, H, Ardeshna, K, Goto, H, Barbui, AM, Abramson, JS, Borchmann, P, Fleury, I, Mielke, S, Skarbnik, A, de Vos, S, Kamdar, M, Karmali, R, Viardot, A, Farazi, T, Fasan, O, Lymp, J, Vedal, M, Nishii, R, Avilion, A, Papuga, J, Nastoupil, LJ

Get full text

HIGH RESPONSE RATES WITH PEMBROLIZUMAB IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA: INTERIM RESULTS OF AN ON OPEN‐LABEL, PHASE II STUDY by Nastoupil, L.J., Westin, J., Fowler, N., Fanale, M., Samaniego, F., Oki, Y., Obi, C., Cao, J., Cheng, X., Ma, M., Wang, Z., Chu, F., Feng, L., Zhou, S., Davis, R.E., Neelapu, S.S.

Get full text

Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma by Oncale, Melody B, Maymani, Hossein, Nastoupil, Loretta J

“…Immunotherapy is a rapidly evolving therapeutic option in the treatment of lymphoma. Neoplastic cells evade immune recognition through the programmed death…”
Get full text

Treatment Strategies for Patients with Diffuse Large B-Cell Lymphoma: Past, Present, and Future by Sinha, Rajni, Nastoupil, Loretta, Flowers, Christopher R

“…Diffuse large B-cell lymphoma (DLBCL) is the most commonly occurring lymphoma in the Western world. DLBCL is a clinically, biologically, and pathologically…”
Get full text